Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Retained Earnings: 2019-2024

Historic Retained Earnings for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to -$738.8 million.

  • Nurix Therapeutics' Retained Earnings fell 35.99% to -$925.0 million in Q3 2025 from the same period last year, while for Aug 2025 it was -$925.0 million, marking a year-over-year decrease of 35.99%. This contributed to the annual value of -$738.8 million for FY2024, which is 35.50% down from last year.
  • Latest data reveals that Nurix Therapeutics reported Retained Earnings of -$738.8 million as of FY2024, which was down 35.50% from -$545.2 million recorded in FY2023.
  • In the past 5 years, Nurix Therapeutics' Retained Earnings ranged from a high of -$103.7 million in FY2020 and a low of -$738.8 million during FY2024.
  • Over the past 3 years, Nurix Therapeutics' median Retained Earnings value was -$545.2 million (recorded in 2023), while the average stood at -$561.7 million.
  • Data for Nurix Therapeutics' Retained Earnings shows a maximum YoY slumped of 113.01% (in 2021) over the last 5 years.
  • Over the past 5 years, Nurix Therapeutics' Retained Earnings (Yearly) stood at -$103.7 million in 2020, then plummeted by 113.01% to -$220.9 million in 2021, then plummeted by 81.65% to -$401.3 million in 2022, then plummeted by 35.87% to -$545.2 million in 2023, then plummeted by 35.50% to -$738.8 million in 2024.